Nurix Therapeutics Announces Closing of Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
17 April 2024 - 8:21AM
Nurix Therapeutics, Inc. (Nasdaq: NRIX) today announced the
closing of its underwritten public offering of 11,916,667 shares of
its common stock at a public offering price of $15.00 per share,
which includes 1,750,000 shares issued upon the exercise in full by
the underwriters of their option to purchase additional shares of
common stock. In addition, and in lieu of common stock, Nurix sold
to certain investors pre-funded warrants to purchase 1,500,100
shares of common stock at a purchase price of $14.999 per
pre-funded warrant, which represents the per share public offering
price for the common stock less the $0.001 per share exercise price
for each such pre-funded warrant. The net proceeds from the
offering, after deducting underwriting discounts and commissions
and other offering expenses, were approximately $188.6 million.
J.P. Morgan Securities LLC, Piper Sandler &
Co. and Stifel, Nicolaus & Company, Incorporated acted as joint
book-running managers for the offering. RBC Capital Markets, LLC
and Needham & Company, LLC acted as lead managers for the
offering.
The public offering was made pursuant to a shelf
registration statement on Form S-3 (File No. 333-258448) that was
previously filed by Nurix with the Securities and Exchange
Commission (“SEC”) on August 4, 2021, which was subsequently
amended on February 9, 2023, by Post-Effective Amendment No. 1 and
Post-Effective Amendment No. 2 and declared effective on April 6,
2023. The offering was made only by means of a prospectus
supplement and accompanying prospectus. A copy of the final
prospectus supplement may be obtained from: J.P. Morgan Securities
LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue,
Edgewood, NY 11717, by telephone at (866) 803-9204, or via email at
prospectus-eq_fi@jpmchase.com; Piper Sandler & Co., Attention:
Prospectus Department, 800 Nicollet Mall, J12S03, Minneapolis, MN
55402, by telephone at (800) 747-3924, or via email at
prospectus@psc.com; or Stifel, Nicolaus & Company,
Incorporated, Attention: Prospectus Department, One Montgomery
Street, Suite 3700, San Francisco, CA 94104, by telephone at (415)
364-2720, or via email at syndprospectus@stifel.com.
This press release shall not constitute an offer
to sell or the solicitation of an offer to buy any securities of
Nurix, nor shall there be any sale of these securities in any state
or jurisdiction in which such offer, solicitation, or sale would be
unlawful prior to registration or qualification under the
securities laws of any such state or jurisdiction.
About Nurix Therapeutics,
Inc.
Nurix Therapeutics is a clinical stage
biopharmaceutical company focused on the discovery, development and
commercialization of innovative small molecules and antibody
therapies based on the modulation of cellular protein levels as a
novel treatment approach for cancer, inflammatory conditions, and
other challenging diseases. Leveraging extensive expertise in E3
ligases together with proprietary DNA-encoded libraries, Nurix has
built DELigase, an integrated discovery platform, to identify and
advance novel drug candidates targeting E3 ligases, a broad class
of enzymes that can modulate proteins within the cell. Nurix’s drug
discovery approach is to either harness or inhibit the natural
function of E3 ligases within the ubiquitin-proteasome system to
selectively decrease or increase cellular protein levels. Nurix’s
wholly owned, clinical stage pipeline includes targeted protein
degraders of Bruton’s tyrosine kinase, a B-cell signaling protein,
and inhibitors of Casitas B-lineage lymphoma proto-oncogene B, an
E3 ligase that regulates activation of multiple immune cell types
including T cell and NK cells. Nurix is headquartered in San
Francisco, California.
Forward-Looking Statements
This press release contains forward-looking
statements within the meaning of the U.S. Private Securities
Litigation Reform Act of 1995 and other federal securities laws.
Any statements contained herein that do not describe historical
facts are forward-looking statements that involve risks and
uncertainties that could cause actual results to differ materially
from those discussed in such forward-looking statements. Such risks
and uncertainties include, among others, the risks identified in
Nurix’s filings with the SEC, the prospectus related to the
offering, and subsequent filings with the SEC. Any of these risks
and uncertainties could materially and adversely affect Nurix’s
results of operations, which would, in turn, have a significant and
adverse impact on Nurix’s stock price. Nurix cautions you not to
place undue reliance on any forward-looking statements, which speak
only as of the date they are made. Nurix undertakes no obligation
to update publicly any forward-looking statements to reflect new
information, events or circumstances after the date they were made
or to reflect the occurrence of unanticipated events.
Investor Contacts:Jason Kantor,
Ph.DNurix Therapeuticsir@nurixtx.com
Elizabeth Wolffe, Ph.DWheelhouse Life Science
Advisorslwolffe@wheelhouselsa.com
Media Contact:Aljanae Reynolds
Wheelhouse Life Science Advisorsareynolds@wheelhouselsa.com
Nurix Therapeutics (NASDAQ:NRIX)
Historical Stock Chart
From Apr 2024 to May 2024
Nurix Therapeutics (NASDAQ:NRIX)
Historical Stock Chart
From May 2023 to May 2024